Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

A prospective study shows that lower levels of physical exercise are consistently associated with a higher risk for common ...

Visible hyperpigmentation may mask persistent erythema and should not be assumed to indicate resolved inflammation,’ ...

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an ...

Older adults with type 2 diabetes have faster cortical thinning in several brain regions and greater decline in processing ...

In a phase 3 trial, adding a combo of two traditional Chinese meds to metformin reduced A1c and improved lipid measure in ...

A novel ultrasound-derived score combined with liver stiffness measurement can identify both MASH and fibrosis, potentially ...

The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

Laser interstitial thermal therapy (LITT) demonstrates low complication rates in a study of nearly 800 patients with brain ...

Antiviral treatment started within 48 hours of symptom onset is linked to a reduced risk for hospitalization among pediatric ...